Affymax and Takeda aim to submit Hematide to the FDA in 2011

08/5/2010 | Bloomberg Businessweek

Affymax and Japanese partner Takeda Pharmaceutical plan to file for FDA approval of anemia treatment Hematide during the first half of next year. Affymax said it will pursue an application for the treatment of anemia in dialysis patients and continue evaluating the drug's nondialysis use.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI